Deze pagina is automatisch vertaald en de nauwkeurigheid van de vertaling kan niet worden gegarandeerd. Raadpleeg de Engelse versie voor een brontekst.

Farmacokinetisch onderzoek van Venetoclax-tabletten vermalen en opgelost in een oplossing

27 oktober 2026 bijgewerkt door: Children's Hospital Medical Center, Cincinnati

Een farmacokinetisch onderzoek naar Venetoclax-tabletten, vermalen en opgelost in een oplossing bij kinderen en jongvolwassenen met hematologische maligniteiten

The use of venetoclax-based therapies for pediatric patients with relapsed or refractory malignancies is increasingly common outside of the clinical trial setting. For patients who cannot swallow tablets, it is common to crush the tablets and dissolve them in liquid to create a solution. However, no PK data exists in adults or children using crushed tablets dissolved in liquid in this manner, and as a result, the venetoclax exposure with this solution is unknown.

Primary Objectives

• To determine the pharmacokinetics of venetoclax when commercially available tablets are crushed and dissolved into a solution

Secondary Objectives

  • To evaluate the safety of crushed venetoclax tablets administered as an oral solution
  • To determine the pharmacokinetics of venetoclax solution in patients receiving concomitant strong and moderate CYP3A inhibitors
  • To determine potential pharmacokinetic differences based on route of venetoclax solution administration (ie. PO vs NG tube vs G-tube)
  • To determine the concentration of venetoclax in cerebral spinal fluid when administered as an oral solution

Studie Overzicht

Gedetailleerde beschrijving

Peripheral blood will be drawn at multiple time points to evaluate venetoclax pharmacokinetics in patients who are receiving venetoclax solution made from crushed tablets as part of their oncology treatment.

Studietype

Observationeel

Inschrijving (Geschat)

30

Contacten en locaties

In dit gedeelte vindt u de contactgegevens van degenen die het onderzoek uitvoeren en informatie over waar dit onderzoek wordt uitgevoerd.

Studiecontact

  • Naam: Site Public Contact
  • Telefoonnummer: (513) 636-2799
  • E-mail: cancer@cchmc.org

Studie Locaties

    • Colorado
      • Aurora, Colorado, Verenigde Staten, 80045
        • Werving
        • Children's Hospital Colorado
        • Hoofdonderzoeker:
          • Kelly Faulk, MD
        • Contact:
    • Georgia
      • Atlanta, Georgia, Verenigde Staten, 30329
        • Nog niet aan het werven
        • Children's Healthcare of Atlanta - Arthur M. Blank Hospital
        • Contact:
        • Hoofdonderzoeker:
          • Himalee Sabnis, MD, MS
    • Ohio
      • Cincinnati, Ohio, Verenigde Staten, 45229
        • Werving
        • Cincinnati Children's Hospital Medical Center
    • Pennsylvania
      • Philadelphia, Pennsylvania, Verenigde Staten, 19104
        • Werving
        • Children's Hospital of Philadelphia
        • Hoofdonderzoeker:
          • Sarah Tasian, MD
        • Contact:
    • Texas
      • Houston, Texas, Verenigde Staten, 77030
    • Wisconsin
      • Milwaukee, Wisconsin, Verenigde Staten, 53226
        • Werving
        • Children's Hospital of Wisconsin
        • Hoofdonderzoeker:
          • Zachary Graff, MD
        • Contact:
        • Contact:

Deelname Criteria

Onderzoekers zoeken naar mensen die aan een bepaalde beschrijving voldoen, de zogenaamde geschiktheidscriteria. Enkele voorbeelden van deze criteria zijn iemands algemene gezondheidstoestand of eerdere behandelingen.

Geschiktheidscriteria

Leeftijden die in aanmerking komen voor studie

1 seconde tot 38 jaar (Kind, Volwassen)

Accepteert gezonde vrijwilligers

Nee

Geslachten die in aanmerking komen voor studie

Allemaal

Bemonsteringsmethode

Niet-waarschijnlijkheidssteekproef

Studie Bevolking

Patients must be receiving any dose of venetoclax given as a solution made from crushed tablets by mouth (PO) or via nasogastric (NG), or G-tube as prescribed by their treating oncologist.

Patients must be <39 years of age at time of study enrollment.

Beschrijving

Inclusion Criteria:

  • Age: Patients must be <39 years of age at time of study enrollment
  • Diagnosis: Patients may have a diagnosis of any hematologic malignancy
  • Central access: Patients must have an existing venous or arterial access line for PK blood draws
  • Weight requirement: Patients must weigh at least 5.5 kg at the time of enrollment
  • Venetoclax: Patients must be receiving any dose of venetoclax given as a solution made from crushed tablets by mouth (PO) or via nasogastric (NG), or G-tube as prescribed by their treating oncologist.
  • Concurrent chemotherapy medications: Patients may receive venetoclax as a single agent or in combination with any other chemotherapeutic agents.

Exclusion Criteria:

  • Pregnant women are excluded from this study because venetoclax has the potential for teratogenic or abortifacient effects. Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with venetoclax, breastfeeding should be discontinued if the mother is treated with venetoclax.
  • Males or females of reproductive potential may not participate unless they have agreed to use an effective contraceptive method while on study treatment and for six months following completion.

Studie plan

Dit gedeelte bevat details van het studieplan, inclusief hoe de studie is opgezet en wat de studie meet.

Hoe is de studie opgezet?

Ontwerpdetails

  • Observatiemodellen: OTHER
  • Tijdsperspectieven: PROSPECTIVE

Cohorten en interventies

Groep / Cohort
Interventie / Behandeling
Children and Young Adults

Children and Young Adults who are prescribed venetoclax made from crushed tablets as part of their clinical care.

Participants will receive Venetoclax as prescribed by their treating provider as part of their clinical care.

Wat meet het onderzoek?

Primaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Clearance (CL) as measured by PK sampling (Peripheral Blood; Required)
Tijdsspanne: Blood will be collected on one PK day between Days 5-12 after completion of the venetoclax dose ramp-up : within 1hr prior to the administration of venetoclax, then 2hrs, 5hrs, 12hrs, 18hrs and 24hrs after the administration of venetoclax.

PK parameters of venetoclax will be described in peripheral blood including: the observed peak plasma concentration (Cmax)

Blood will be collected on one PK day between Days 5-12 after completion of the venetoclax dose ramp-up : within 1hr prior to the administration of venetoclax, then 2hrs, 5hrs, 12hrs, 18hrs and 24hrs after the administration of venetoclax.
Clearance (CL) as measured by PK sampling (Peripheral Blood; Required)
Tijdsspanne: Blood will be collected on one PK day between Days 5-12 after completion of the venetoclax dose ramp-up : within 1hr prior to the administration of venetoclax, then 2hrs, 5hrs, 12hrs, 18hrs and 24hrs after the administration of venetoclax.

PK parameters of venetoclax will be described in peripheral blood including: the time to peak (Tmax)

Blood will be collected on one PK day between Days 5-12 after completion of the venetoclax dose ramp-up : within 1hr prior to the administration of venetoclax, then 2hrs, 5hrs, 12hrs, 18hrs and 24hrs after the administration of venetoclax.
Clearance (CL) as measured by PK sampling (Peripheral Blood; Required)
Tijdsspanne: Blood will be collected on one PK day between Days 5-12 after completion of the venetoclax dose ramp-up : within 1hr prior to the administration of venetoclax, then 2hrs, 5hrs, 12hrs, 18hrs and 24hrs after the administration of venetoclax.

PK parameters of venetoclax will be described in peripheral blood including: the apparent terminal phase elimination rate constant (β)

Blood will be collected on one PK day between Days 5-12 after completion of the venetoclax dose ramp-up : within 1hr prior to the administration of venetoclax, then 2hrs, 5hrs, 12hrs, 18hrs and 24hrs after the administration of venetoclax.
Clearance (CL) as measured by PK sampling (Peripheral Blood; Required)
Tijdsspanne: Blood will be collected on one PK day between Days 5-12 after completion of the venetoclax dose ramp-up : within 1hr prior to the administration of venetoclax, then 2hrs, 5hrs, 12hrs, 18hrs and 24hrs after the administration of venetoclax.

PK parameters of venetoclax will be described in peripheral blood including: the terminal-phase elimination half-life (T1/2)

Blood will be collected on one PK day between Days 5-12 after completion of the venetoclax dose ramp-up : within 1hr prior to the administration of venetoclax, then 2hrs, 5hrs, 12hrs, 18hrs and 24hrs after the administration of venetoclax.
Clearance (CL) as measured by PK sampling (Peripheral Blood; Required)
Tijdsspanne: Blood will be collected on one PK day between Days 5-12 after completion of the venetoclax dose ramp-up : within 1hr prior to the administration of venetoclax, then 2hrs, 5hrs, 12hrs, 18hrs and 24hrs after the administration of venetoclax.

PK parameters of venetoclax will be described in peripheral blood including: the areas under plasma concentration curve (AUC) over a 24-hour dose interval (AUC0-24) or for infinite time (AUC0-∞)

Blood will be collected on one PK day between Days 5-12 after completion of the venetoclax dose ramp-up : within 1hr prior to the administration of venetoclax, then 2hrs, 5hrs, 12hrs, 18hrs and 24hrs after the administration of venetoclax.
Clearance (CL) as measured by PK sampling (Peripheral Blood; Required)
Tijdsspanne: Blood will be collected on one PK day between Days 5-12 after completion of the venetoclax dose ramp-up : within 1hr prior to the administration of venetoclax, then 2hrs, 5hrs, 12hrs, 18hrs and 24hrs after the administration of venetoclax.

PK parameters of venetoclax will be described in peripheral blood including: oral clearance (CL/F) of venetoclax

Blood will be collected on one PK day between Days 5-12 after completion of the venetoclax dose ramp-up : within 1hr prior to the administration of venetoclax, then 2hrs, 5hrs, 12hrs, 18hrs and 24hrs after the administration of venetoclax.
Clearance (CL) as measured by PK sampling (Cerebrospinal Fluid; Optional)
Tijdsspanne: Around Days 8, 15, 22, and/or 28, all +/- 3 days. Not all patients will have CSF collected at these time points.

PK parameters of venetoclax will be described in cerebral spinal fluid including: the observed peak plasma concentration (Cmax)

Around Days 8, 15, 22, and/or 28, all +/- 3 days. Not all patients will have CSF collected at these time points.
Clearance (CL) as measured by PK sampling (Cerebrospinal Fluid; Optional)
Tijdsspanne: Around Days 8, 15, 22, and/or 28, all +/- 3 days. Not all patients will have CSF collected at these time points.

PK parameters of venetoclax will be described in cerebral spinal fluid including: the time to peak (Tmax)

Around Days 8, 15, 22, and/or 28, all +/- 3 days. Not all patients will have CSF collected at these time points.
Clearance (CL) as measured by PK sampling (Cerebrospinal Fluid; Optional)
Tijdsspanne: Around Days 8, 15, 22, and/or 28, all +/- 3 days. Not all patients will have CSF collected at these time points.

PK parameters of venetoclax will be described in cerebral spinal fluid including: the apparent terminal phase elimination rate constant (β)

Around Days 8, 15, 22, and/or 28, all +/- 3 days. Not all patients will have CSF collected at these time points.
Clearance (CL) as measured by PK sampling (Cerebrospinal Fluid; Optional)
Tijdsspanne: Around Days 8, 15, 22, and/or 28, all +/- 3 days. Not all patients will have CSF collected at these time points.

PK parameters of venetoclax will be described in cerebral spinal fluid including: the terminal-phase elimination half-life (T1/2)

Around Days 8, 15, 22, and/or 28, all +/- 3 days. Not all patients will have CSF collected at these time points.
Clearance (CL) as measured by PK sampling (Cerebrospinal Fluid; Optional)
Tijdsspanne: Around Days 8, 15, 22, and/or 28, all +/- 3 days. Not all patients will have CSF collected at these time points.

PK parameters of venetoclax will be described in cerebral spinal fluid including: the areas under plasma concentration curve (AUC) over a 24-hour dose interval (AUC0-24) or for infinite time (AUC0-∞)

Around Days 8, 15, 22, and/or 28, all +/- 3 days. Not all patients will have CSF collected at these time points.
Clearance (CL) as measured by PK sampling (Cerebrospinal Fluid; Optional)
Tijdsspanne: Around Days 8, 15, 22, and/or 28, all +/- 3 days. Not all patients will have CSF collected at these time points.

PK parameters of venetoclax will be described in cerebral spinal fluid including: oral clearance (CL/F)

Around Days 8, 15, 22, and/or 28, all +/- 3 days. Not all patients will have CSF collected at these time points.

Medewerkers en onderzoekers

Hier vindt u mensen en organisaties die betrokken zijn bij dit onderzoek.

Onderzoekers

  • Hoofdonderzoeker: Lauren Pommert, MD, Children's Hospital Medical Center, Cincinnati

Studie record data

Deze datums volgen de voortgang van het onderzoeksdossier en de samenvatting van de ingediende resultaten bij ClinicalTrials.gov. Studieverslagen en gerapporteerde resultaten worden beoordeeld door de National Library of Medicine (NLM) om er zeker van te zijn dat ze voldoen aan specifieke kwaliteitscontrolenormen voordat ze op de openbare website worden geplaatst.

Bestudeer belangrijke data

Studie start (Werkelijk)

15 november 2023

Primaire voltooiing (Geschat)

1 december 2026

Studie voltooiing (Geschat)

1 december 2027

Studieregistratiedata

Eerst ingediend

24 oktober 2023

Eerst ingediend dat voldeed aan de QC-criteria

8 november 2023

Eerst geplaatst (Werkelijk)

14 november 2023

Updates van studierecords

Laatste update geplaatst (Werkelijk)

29 oktober 2026

Laatste update ingediend die voldeed aan QC-criteria

27 oktober 2026

Laatst geverifieerd

1 oktober 2026

Meer informatie

Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .

Abonneren